Steps taken after granting the Marketing Authorisation 
For procedures finalised after 1 December 2003 please refer to module 8B. 
• 
• 
• 
• 
• 
• 
• 
• 
• 
• 
• 
On  27  September  2000  the  MAH  submitted  a  Type  II  variation  (II/01)  to  extend  the  clinical 
indication,  mainly  to  include  the  treatment  of  subfoveal  CNV  due  to  pathological  myopia.  In 
addition,  the  opportunity  was  taken  to  amend  the  SPC  with  regard  to  pre-clinical  safety 
information,  and  with  updated  clinical  safety  information  arising  from  post-marketing  safety 
studies and PSUR reports. The CPMP gave a positive opinion on this variation on 14 December 
2000, and the Commission Decision was issued on 20 March 2001. 
On  30  November  2000,  the  EMEA  issued  a  Notification  of  approval  for  a  Type  I  variation  
(I/02) to change the name of the MAH from CIBAVision Europe Ltd to Novartis Ophthalmics 
Europe  Ltd,  together  with  a  change  of  address.  The  corresponding  Commission  Decision  was 
issued on 16 February 2001.  
On 16 February 2001, the EMEA issued a Notification of approval for a Type I variation (I/03) 
to change the analytical test method for the average particle size assay of the finished product.  
On 27 June 2001, the EMEA issued a Notification of approval for a Type I variation (I/04) to 
extend the shelf life from 2 years to 3 years. This change was incorporated in the Annexes of the 
CPMP opinion for the Type I variation above, and in the Commission Decision of 10 September 
2001. 
On 7 November 2001, the EMEA issued a Notification of approval for a Type I variation (I/06) 
to extend the retest period of the active substance from 24 months to 36 months at the approved 
storage conditions. 
On  5  November  2001  the  MAH  submitted  a  Type  II  variation  application  (II/07)  to  add  an 
additional manufacturer and to make changes to the manufacturing process. The CPMP gave a 
positive opinion on this variation on 17 January 2002, and the Commission Decision was issued 
on 11 February 2002. 
On  10  December  2001  the  MAH  submitted  a  Type  II  variation  application  (II/08)  to  update 
sections  4.4  and  4.8  of  the  SPC  and  the  corresponding  section  4  of  the  Package  Leaflet  as 
requested by the CPMP following the assessment of the second PSUR. Furthermore, the same 
sections  are  revised  following  the  assessment  of  the  data  submitted  as  follow  up  to  the  first 
PSUR.  The  CPMP  gave  a  positive  opinion  on  this  variation  on  21  February  2002,  and  the 
Commission Decision was issued on 24 May 2002. 
On 10 September 2001 the MAH submitted a Type II variation application (II/05) to extend the 
therapeutic indication to include the indication of occult subfoveal choroidal neovascularisation 
due to age-related macular degeneration. The CPMP gave a positive opinion on this variation on 
30 May 2002, and the Commission Decision was issued on 22 August 2002. 
On 10 December 2001 the MAH submitted a Type II variation application (II/09) for an update 
of sections 5.1 of the SPC to add the clinical results of study BPD OCR 003 PM at 24 months. 
The  CPMP  gave  a  positive  opinion  on  this  variation  on  30  May  2002,  and  the  Commission 
Decision was issued on 22 August 2002. 
On 5 September 2002, the EMEA issued a Notification of approval for a Type I variation (I/10) 
to introduce minor changes in manufacture of the medicinal product. 
On 9 September 2002 the MAH submitted a Type II variation application (II/12) to apply for a 
change of in-process controls of the finished product and to discontinue two sample tests. The 
CPMP  gave  a  positive  opinion  on  this  variation  on  21  November  2002,  and  the  European 
Commission acknowledged receipt on 27 November 2002. 
1/2 
EMEA 2004 
 
 
 
 
• 
• 
• 
On 4 December 2002, the EMEA issued a Notification of approval for a Type I variation (I/13) 
to change the packaging site (labelling and secondary packaging), batch control site, and batch 
release site from Laboratories CIBA Vision Faure, Annonay, France, to Novartis Pharma S.A.S., 
Huningue,  France.  In  addition,  Novartis  Ophthalmics  applied  for  a  change  of  the  local 
representative in France from Novartis Ophthalmics S.A., Rueil-Malmaison to Novartis Pharma 
S.A.S., Rueil-Malmaison. The Commission Decision was issued on 14 January 2003. 
On 8 July 2003 the Marketing authorisation Holder submitted an application for the transfer of 
the  Marketing  Authorisation  for  Visudyne  from  Novartis  Ophtalmics  Europe  Ltd.  to  Novartis 
Europharm  Limited,  United  Kingdom.  The  transfer  was  approved  by  the  EMEA  on  4  August 
2003. The EMEA notified the European Commission, who amended the Commission Decision 
on 22 September 2003. 
On  17  November  2003,  the  EMEA  issued  a  Notification  of  approval  for  a  Type  IB  variation 
(I/15) to introduce minor changes in manufacture of the finished product. 
2/2 
EMEA 2004 
 
 
 
 
